Ads
related to: which atorvastatin was recalled better than drugsThis free app will find the best local deals. - AOL.com
Search results
Results from the WOW.Com Content Network
From 1996 to 2012, under the trade name Lipitor, atorvastatin became the world's best-selling medication of all time, with more than $125 billion in sales over approximately 14.5 years. [ 116 ] and $13 billion a year at its peak, [ 117 ] Lipitor alone "provided up to a quarter of Pfizer Inc.'s annual revenue for years."
(WJW) — A popular anxiety drug is being recalled over a ‘life-threatening’ label mistake. In a recall alert for some lots of Clonazepam Orally Disintegrating Tablets the FDA states the ...
Sales of Pfizer's Lipitor topped out at more than $10 billion before the drug finally lost patent protection. The next generation of cholesterol-lowering drugs are on their way, and it's clear ...
Diversion, abuse, and a relatively high rate of overdose deaths in comparison to other drugs of its group. This drug continues to be available in most of the world including the US, but under strict controls. Terfenadine (Seldane, Triludan) 1997–1998 France, South Africa, Oman, others, US Prolonged QT interval; ventricular tachycardia [2] [3]
As part of this investigation, the FDA initiated a recall of more than 18 million Lipitor tablets, which ranks as the largest recall in the history of criminal investigations of counterfeit medications. [21] [22] Participants in this scheme conspired to purchase and sell counterfeit, misbranded and illegally imported drugs.
Pfizer (PFE) has announced the fourth recall of its blockbuster cholesterol drug Lipitor. The largest pharmaceutical in the world said that it intends to recall approximately 19,000 bottles of ...
With median follow-up of 6 years, simvastatin+ezetimibe was found to reduce the primary outcome of CV mortality, major CV event, or nonfatal stroke (34.7% vs. 32.7%; P=0.016; NNT 50 per 7 years or NNT 350 per 1 year ). There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke. [6]
With policy reform, drug recalls, medical breakthroughs and plenty of layoffs, 2010 proved to be an exciting -- if not entirely positive -- year for health care. The passage of the controversial ...